Name: Abamune
SKU: 26117
Availability: InStock

🏷️ Parameter	🔍 Details
🧬 Active Ingredient	Abacavir Sulfate
💊 Indication	HIV-1 Infection (part of combination ART)
🇺🇸 US Brand	Ziagen®
🏭 Manufacturer	Cipla Ltd.
📦 Packaging	30 tablets in 1 HDPE bottle
💪 Strength	300 mg
🚚 Delivery Time	7–14 days (Worldwide)

⚙️ Introduction to Abamune

Abamune by Cipla contains Abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) for HIV-1 treatment. Critical considerations:

🧬 Mandatory HLA-B*5701 screening before initiation (fatal hypersensitivity risk in positive patients)
❤️ Increased myocardial infarction risk in patients with cardiac risk factors
✅ Preferred for patients with renal impairment (no dose adjustment needed)
⚠️ Black-box warning for hypersensitivity reactions (fever, rash, multi-organ involvement)

Cipla’s 30-tablet bottle provides a month’s supply for combination regimens like Abacavir+Lamivudine+Dolutegravir.

💊 Dosage & Indications

💉 Indication	🧪 Dosage	⏱️ Frequency	💡 Notes
Adults	600 mg/day	Once daily or 300 mg BID	HLA-B5701 negative only*
Children ≥25kg	300 mg BID	Twice daily	Oral solution for <25kg
Renal Impairment	No adjustment needed	–	Preferred over TDF
Hepatic Impairment	Avoid in severe cirrhosis	Contraindicated	↓ Metabolism

⚠️ Side Effects, Storage & Warnings

❗ Common Side Effects:
- Nausea (19%)
- Headache (13%)
- Fatigue (9%)
🚫 Life-Threatening Effects:
- Hypersensitivity reaction (fever, rash, respiratory failure)
- Myocardial infarction (in high-risk patients)
- Lactic acidosis
❄️ Storage: 15–30°C; keep bottle tightly closed (desiccant included).
⚠️ Critical Warnings:
- Contraindicated without confirmed HLA-B*5701 negative status
- Discontinue permanently if hypersensitivity suspected
- Monitor cardiovascular risk factors biannually

🌍 Global Availability & Shipping

🌎 Region	📦 Shipping	💵 Price (30-tablet bottle)	📜 Prescription
🇺🇸 USA	✅ Yes	$45–$80	Required
🇬🇧 UK	✅ Yes	£35–£65	Required
🇦🇺 Australia	✅ Yes	AUD 60–100	Required

🔗 Related Indian Alternatives (Different in Same Category)

💊 Product Name	🏭 Manufacturer	🔗 Internal Link
Tenvir (Tenofovir)	Cipla	tenvir
Lamivir (Lamivudine)	Cipla	lamivir
Viraday (Efavirenz/FTC/TDF)	Cipla	viraday
Taffic (Bictegravir/TAF/FTC)	Hetero	taffic
Dolutranz (Dolutegravir/Tenofovir)	Mylan	dolutranz
Abamune-L (Abacavir/Lamivudine)	Cipla	abamune-l

📚 External Medical References

🩺 Expert Commentary

Dr. Priya Desai, HIV Pharmacologist:
“Abamune’s renal safety makes it ideal for older patients but demands strict HLA-B5701 screening. For those with cardiovascular risks, [tenvir] (Tenofovir) is safer. Cipla’s bottle includes a hypersensitivity warning card – ensure patients carry it at all times.”*

📌 Disclaimer

This information is not medical advice. Use under physician supervision. Cipla’s Abamune carries black-box warnings for fatal hypersensitivity reactions.

💡 Clinical Protocol:

Hypersensitivity Reaction (HSR) Management:

Symptom Onset Action

Within 6 weeks Permanent discontinuation

Fever + Rash ER visit immediately

Respiratory symptoms Epinephrine + corticosteroids
Cardiovascular Monitoring:

Parameter Frequency Action Threshold

Blood Pressure Quarterly >140/90 mmHg

Lipid Profile Biannual LDL >160 mg/dL

ECG Baseline Ischemic changes
Bottle Specifications:
- Amber HDPE bottle with induction seal
- Tablet ID: “ABA300” engraving
- Hypersensitivity warning card included

Drug Interactions:

Concomitant Drug	Risk	Action
Ethanol	↑ Abacavir levels 40%	Avoid excessive alcohol
Methadone	No interaction	Safe for MAT patients
Ribavirin	↑ Lactic acidosis risk	Avoid concurrent use

HLA-B*5701 Screening Protocol:
1. Test before first prescription
2. Document negative result in medical record
3. Re-testing unnecessary if negative